Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0Endoscopy International Open

Indication-Specific Adverse Events and Temporal Trends of Lumen-Apposing Metal Stents: A National Postmarketing Surveillance Analysis (2020–2025)

4 affiliations
  1. 1Gastroenterology University of Illinois Chicago College of Medicine at Peoria Peoria Illinois United States
  2. 2Center for Interventional Endoscopy AdventHealth Orlando Orlando Florida United States
  3. 3Gastroenterology Brigham and Women’s Hospital Boston Massachusetts United States
  4. 4Medicine University of Central Florida Orlando Florida United States

Abstract

Background and Aims The AXIOS stent is a lumen-apposing metal stent widely used for endoscopic ultrasound-guided drainage of pancreatic fluid collections, biliary drainage, and gastroenterostomy. We analyzed device problems and patient adverse events reported to the FDA Manufacturer and User Facility Device Experience (MAUDE) database (2020–2025) with indication-specific risk stratification.

Methods We performed a retrospective analysis of 1775 AXIOS adverse event reports from the FDA MAUDE database, systematically classified by procedural indication, device problem, and patient outcome. Each report was assigned to a single highest-severity category, and within-indication proportions were calculated.

Results Annual reports increased by 232%, from 144 in 2020 to 478 in 2025. The indications comprised pancreatic drainage (46.2%), biliary drainage (35.7%), and gastroenterostomy (9.5%). Device problems included positioning/malpositioning (59.0%), distal flange activation failure (19.4%), migration (7.3%), and proximal detachment (4.5%). Gastroenterostomy carried the highest within-indication proportions of mortality (11.8%), perforation (6.5%), and infection (4.1%), exceeding biliary (3.9%, 6.3%, 1.4%) and pancreatic drainage (2.3%, 3.7%, 1.5%).

Conclusions AXIOS adverse event reporting increased by 232% from 2020 to 2025, reflecting expanding utilization and enhanced surveillance. Gastroenterostomy carried the highest within-indication burden of serious adverse events. The marked rise in distal flange activation failures—coinciding with December 2025 manufacturer field safety notice—demonstrates postmarketing surveillance value and underscores the need for indication-specific risk stratification and prospective registries capturing operator- and device-level detail that passive surveillance cannot provide.

Related

  1. Early postmarketing reporting patterns of resmetirom in FAERS: disproportionality analyses with indication-restricted and active comparators
    Xin Zhao, Bi Pan, Tianhao Chen +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyFrontiersCrossrefPMC
  2. Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan
    Tadao Akizawa, Kyomi Kanaya, Kiyomi Aizawa +5
    Therapeutic Apheresis and DialysisPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  3. Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis
    Samuel A. Fisch, Eitan J. Neugut, Nicole Cornet +3
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  4. Initial Gastrectomy Indication Is Associated with Divergent Temporal Patterns of Remnant Gastric Cancer After Billroth II Reconstruction: A Retrospective Study
    Yining Sun, Bingcan Yang, Feifan Chen +3
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
  5. Temporal trends and geographical inequalities in congenital anomaly mortality in China, 2008–2021: a population-based surveillance study
    Mingliang Tai, Zihao Bai, Sizhe Lu +4
    BMC Public HealthPeer-reviewedCC BY-NC-ND 4.0Surgery & anaesthesiaCrossref
BibTeX
@article{vohra2026indicationspecific,
  title = {{Indication-Specific Adverse Events and Temporal Trends of Lumen-Apposing Metal Stents: A National Postmarketing Surveillance Analysis (2020–2025)}},
  author = {Ishaan Vohra and Muhammad K. Hasan and Harishankar Gopakumar and Dennis Yang and Deepanshu Jain and Natalie Cosgrove and Maham Hayat and Ranya Ahmed and Abdul Mohammed and Zubair Khan and Carlos-Rodriguez Bertran and Mustafa A. Arain},
  journal = {Endoscopy International Open},
  year = {2026},
  month = oct,
  doi = {10.1055/a-2979-6046},
  url = {https://doi.org/10.1055/a-2979-6046},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Indication-Specific Adverse Events and Temporal Trends of Lumen-Apposing Metal Stents: A National Postmarketing Surveillance Analysis (2020–2025)
AU  - Ishaan Vohra
AU  - Muhammad K. Hasan
AU  - Harishankar Gopakumar
AU  - Dennis Yang
AU  - Deepanshu Jain
AU  - Natalie Cosgrove
AU  - Maham Hayat
AU  - Ranya Ahmed
AU  - Abdul Mohammed
AU  - Zubair Khan
AU  - Carlos-Rodriguez Bertran
AU  - Mustafa A. Arain
PY  - 2026
DA  - 2026/10/21
JO  - Endoscopy International Open
DO  - 10.1055/a-2979-6046
UR  - https://doi.org/10.1055/a-2979-6046
AB  - Background and Aims The AXIOS stent is a lumen-apposing metal stent widely used for endoscopic ultrasound-guided drainage of pancreatic fluid collections, biliary drainage, and gastroenterostomy. We analyzed device problems and patient adverse events reported to the FDA Manufacturer and User Facility Device Experience (MAUDE) database (2020–2025) with indication-specific risk stratification.  Methods We performed a retrospective analysis of 1775 AXIOS adverse event reports from the FDA MAUDE database, systematically classified by procedural indication, device problem, and patient outcome. Each report was assigned to a single highest-severity category, and within-indication proportions were calculated.  Results Annual reports increased by 232%, from 144 in 2020 to 478 in 2025. The indications comprised pancreatic drainage (46.2%), biliary drainage (35.7%), and gastroenterostomy (9.5%). Device problems included positioning/malpositioning (59.0%), distal flange activation failure (19.4%), migration (7.3%), and proximal detachment (4.5%). Gastroenterostomy carried the highest within-indication proportions of mortality (11.8%), perforation (6.5%), and infection (4.1%), exceeding biliary (3.9%, 6.3%, 1.4%) and pancreatic drainage (2.3%, 3.7%, 1.5%).  Conclusions AXIOS adverse event reporting increased by 232% from 2020 to 2025, reflecting expanding utilization and enhanced surveillance. Gastroenterostomy carried the highest within-indication burden of serious adverse events. The marked rise in distal flange activation failures—coinciding with December 2025 manufacturer field safety notice—demonstrates postmarketing surveillance value and underscores the need for indication-specific risk stratification and prospective registries capturing operator- and device-level detail that passive surveillance cannot provide.
SN  - 2364-3722
SN  - 2196-9736
ER  -